This study therefore investigated the therapeutic potential of WT161, a selective HDAC6 inhibitor, focusing on its role in targeting of the VLA-4/Focal adhesion kinase (FAK) signaling pathway in ALL. The gene discussed is PTK2; the disease is acute lymphoblastic leukemia.